Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia

References

• Tallal L, Tan C, Oettgen H, et al.E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970; 25:306–320.
   PubMedGoogle Scholar
• Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97–113.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166–78.
   PubMed Web of Science ®Google Scholar
• Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park) 2011;25:328–35.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger S, Boos J et al. L-asparaginase treatment in acute lymphoblastic leukemia. Cancer 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013;25 Suppl 1:S1–9.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525–32.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002;38:310–6.
   PubMedGoogle Scholar
• Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893–901.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Chen SH, Pei D, Yang W, Cheng C, Jeha S et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 2010;88:191–6.
   PubMed Web of Science ®Google Scholar
• Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405–96.
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Shneider NA, Axel R. A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron 1990;5:569–581.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Relling MV. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clinical Oncol 2000;18:1525–1532.
   PubMed Web of Science ®Google Scholar
• Nakanishi S, Masu M. Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct 1994;23:319–48.
   PubMedGoogle Scholar
• Nakagawa T. The biochemistry, ultrastructure, and subunit assembly mechanism of AMPA receptors. Mol Neurobiol 2010;42:161–84
   PubMed Web of Science ®Google Scholar
• Sommer B, Keinänen K, Verdoorn TA, Wisden W, Burnashev N et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 1990;249:1580–5.
   PubMed Web of Science ®Google Scholar
• Monyer H, Seeburg PH, Wisden W. Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron 1991;6:799–810.
   PubMed Web of Science ®Google Scholar
• Simpson L, Emeson RB. RNA editing. Ann Rev Neurosci 1996;19: 27–52.
   PubMed Web of Science ®Google Scholar
• Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 2008; 8:460–71.
   PubMed Web of Science ®Google Scholar
• Franco R, Pacheco R, Lluis C, Ahern GP, O’Connell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol 2007;28:400–7.
   PubMed Web of Science ®Google Scholar
• Boldyrev AA, Carpenter DO, Johnson P. Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem 2005;95:913–8.
   PubMed Web of Science ®Google Scholar
• Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. Human T-cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J. Immunol 2003;170:4362–4372.
   PubMed Web of Science ®Google Scholar
• Boldyrev AA, Kazey VI, Leinsoo TA, Mashkina AP, Tyulina OV et al. Rodent lymphocytes express functionally active glutamate receptors. Biochem Biophys Res Commun 2004;324:133–139.
   PubMed Web of Science ®Google Scholar
• Vandebriel RJ. Gene polymorphisms within the immune system that may underlie drug allergy. Naunyn Schmiedebergs Arch Pharmacol 2004;369:125–32.
   PubMed Web of Science ®Google Scholar
• Feske S. Ca(2+) influx in T cells: how many ca(2+) channels? Front Immunol 2013;4:99. doi: 10.3389/fimmu.2013.00099
   PubMedGoogle Scholar
• Egebjerg J, Kukekov V, Heinemann SF. Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence. Proc Natl Acad Sci USA 1994;91:10270–4.
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies. Am J Epidemiol 2009;169:505–14. doi: 10.1093/aje/kwn359.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Möricke A, Reiter A, Henze G, Welte K et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr 2013;225 Suppl 1:S62–72.
   PubMed Web of Science ®Google Scholar
• Möricke A, Lauten M, Beier R, Odenwald E, Stanulla M et al. Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Klin Padiatr 2013;225 Suppl 1:S50–6. doi: 10.1055/s-0033-1337964.
   Google Scholar
• Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–84. doi: 10.1038/leu.2009.257.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011;117:238–49.
   PubMed Web of Science ®Google Scholar
• Bussolati O, Belletti S, Uggeri J, Gatti R, Orlandini G, Dall’Asta V et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res 1995; 220:283–291.
   PubMed Web of Science ®Google Scholar
• Yang L, Panetta JC, Cai X, Yang W, Pei D et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932–9.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr R et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211–8.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, Jedrychowska-Dańska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931–6.
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893–901.
   PubMed Web of Science ®Google Scholar
• Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006;107:4244–4249.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780–1786.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Oncol 2010;32:554–563.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of antiasparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009;9:113–116.
   PubMed Web of Science ®Google Scholar
• Boulter J, Hollmann M, O Shea-Greenfield A, Hartley M, Deneris E et al. Molecular cloningand functional expression of glutamate receptor subunit genes. Science 1990;249:1033–1037.
   PubMed Web of Science ®Google Scholar
• Hollmann M, O Shea-Greenfield A, Rogers SW, Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature 1989;342:643–648.
   PubMed Web of Science ®Google Scholar
• Keinanen K, Wisden W, Sommer B, Werner P, Herb A et al. A family of AMPA-selective glutamate receptors. Science 1990;249:556–560.
   PubMed Web of Science ®Google Scholar
• Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron–exon structure determines position and efficiency. Cell 1993;75:1361–1370.
   PubMed Web of Science ®Google Scholar
• Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T et al. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 1992;357:70–74.
   PubMed Web of Science ®Google Scholar
• Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature 1991;354:31–37.
   PubMed Web of Science ®Google Scholar
• Armstrong N, Sun Y, Chen GQ, Gouaux E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature 1998; 395:913–917.
   PubMed Web of Science ®Google Scholar
• Greger IH, Akamine P, Khatri L, Ziff EB. Developmentally regulated, combinatorial RNA processing modulates AMPA receptor biogenesis. Neuron 2006;51:85–97.
   PubMed Web of Science ®Google Scholar
• Seeburg PH, Hartner J. Regulation of ion channel/neurotransmitter receptor functions by RNA editing. Curr Opin Neurobiol 2003;13:279–83.
   PubMed Web of Science ®Google Scholar
• Pacheco R, Gallart T, Lluis C, Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol 2007;185:9–19.
   PubMed Web of Science ®Google Scholar
• Barbon A, Barlati S. Glutamate receptor RNA editing in health and disease. Biochemistry (Mosc) 2011;76:882–9.
   PubMed Web of Science ®Google Scholar
• Noguchi E, Shibasaki M, Arinami T, Takeda K, Maki T et al. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med 1997;156:1390–1393.
   PubMed Web of Science ®Google Scholar
• Beyer K, Nickel R, Freidhoff L, Björkstén B, Huang SK et al. Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J Invest Dermatol 2000;115:906–908.
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, Date M, Bashford D et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 2014 Jun 26. [Epub ahead of print]
   Web of Science ®Google Scholar